Compare Ginkgo Bioworks Holdings Inc (DNA) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Hilton Hotels Corporation Common Stock trades at $326 (market cap $74.18B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 125.6× Ginkgo Bioworks Holdings Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | HLT | |
|---|---|---|
Market Cap | $590.53M | $74.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $350.22 |
52-Week Low | $5.48 | $256.75 |
Enterprise Value | $627.78M | $86.68B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Hilton Worldwide (HLT) trades at $322.45, down 3.88% amid bearish technical signals, though it maintains strong fundamentals with consistent earnings beats and revenue growth to $12.04B in 2025. Analyst consensus remains bullish with a $340.50 price target, supported by 55% buy ratings. Recent news highlights brand campaigns and renovations, while financials show robust cash flow but rising debt levels.
The stock offers upside to analyst targets but faces near-term technical pressure and leverage concerns. Investment appeal hinges on execution of growth initiatives and debt management, with risks including economic sensitivity and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
